Northwest Biotherapeutics (NWBO) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$0.16.
- Northwest Biotherapeutics' Debt to Equity rose 5842.01% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.16, marking a year-over-year increase of 5842.01%. This contributed to the annual value of -$0.23 for FY2024, which is 4814.83% up from last year.
- According to the latest figures from Q3 2025, Northwest Biotherapeutics' Debt to Equity is -$0.16, which was up 5842.01% from -$0.18 recorded in Q2 2025.
- Over the past 5 years, Northwest Biotherapeutics' Debt to Equity peaked at -$0.01 during Q3 2023, and registered a low of -$1.06 during Q4 2021.
- For the 5-year period, Northwest Biotherapeutics' Debt to Equity averaged around -$0.54, with its median value being -$0.44 (2023).
- Its Debt to Equity has fluctuated over the past 5 years, first soared by 9797.56% in 2023, then plummeted by 242025.97% in 2024.
- Over the past 5 years, Northwest Biotherapeutics' Debt to Equity (Quarter) stood at -$1.06 in 2021, then soared by 36.51% to -$0.68 in 2022, then surged by 33.62% to -$0.45 in 2023, then surged by 48.15% to -$0.23 in 2024, then soared by 33.3% to -$0.16 in 2025.
- Its Debt to Equity was -$0.16 in Q3 2025, compared to -$0.18 in Q2 2025 and -$0.17 in Q1 2025.